1. INTRODUCTION:

Topical drug delivery represents one of the most widely utilized therapeutic approaches for the management of dermatological disorders, owing to its ability to deliver active pharmaceutical ingredients directly to the site of action while minimizing systemic exposure. Conventional topical formulations such as creams, lotions, and gels are commonly employed to treat conditions including fungal infections, inflammatory dermatoses, acne, and scalp disorders. However, the therapeutic performance of many topical formulations remains limited due to the formidable barrier properties of the skin, particularly the outermost layer known as the stratum corneum, which restricts the penetration of most drug molecules into deeper skin structures¹.

Over the past two decades, increasing research attention has been directed toward developing advanced strategies capable of enhancing drug penetration and localization within specific skin compartments. Among the various cutaneous pathways available for drug transport, the hair follicle has emerged as a highly promising target for localized drug delivery. Hair follicles represent complex appendageal structures extending deep into the dermal layers and are surrounded by a dense network of sebaceous glands, capillaries, and immune cells. Due to their unique anatomical architecture, hair follicles can act as efficient reservoirs for drug molecules, enabling prolonged retention and controlled release of therapeutic agents at the target site².

The follicular route offers several advantages over conventional transdermal diffusion pathways. Unlike the compact lipid matrix of the stratum corneum, follicular openings provide relatively less resistant entry points for nanoscale drug carriers and particulate systems. Studies have demonstrated that nanoparticles within specific size ranges can preferentially accumulate within hair follicles and remain retained for extended periods, thereby improving the localized concentration of drugs in the pilosebaceous unit. This property is particularly advantageous for the treatment of disorders that originate within or around hair follicles, such as acne vulgaris, androgenetic alopecia, folliculitis, and dandruff ^3,4.

Recent advances in pharmaceutical nanotechnology have significantly accelerated the development of follicle-targeted drug delivery systems. Various nanoscale carriers—including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, nanoemulsions, and vesicular systems have been investigated for their ability to enhance follicular penetration and improve therapeutic efficacy. These carriers can be engineered with specific physicochemical properties such as particle size, surface charge, deformability, and lipid composition to optimize their interaction with follicular structures and sebaceous environments⁵.

In addition to synthetic drugs, increasing attention has also been directed toward incorporating natural bioactive compounds and herbal extracts into follicular delivery systems. Many plant-derived compounds exhibit antifungal, anti-inflammatory, and antioxidant properties that can be beneficial in the management of scalp disorders. However, the therapeutic potential of these phytoconstituents is often limited by poor solubility, instability, and inadequate skin penetration. Nanocarrier-based follicular delivery systems offer promising opportunities to overcome these limitations by enhancing drug stability, improving follicular deposition, and facilitating controlled drug release within the pilosebaceous unit⁶.

Despite the promising advantages associated with follicle-targeted drug delivery, several scientific and technological challenges remain. The complex structure of the skin, variability in follicular density across different anatomical regions, and difficulties in accurately evaluating follicular drug deposition present important obstacles to the clinical translation of these systems. Furthermore, issues related to formulation stability, large-scale manufacturing, and regulatory approval must be carefully addressed before such delivery systems can be widely adopted in dermatological therapy⁷.

Therefore, a comprehensive understanding of the anatomical characteristics of hair follicles, the mechanisms governing follicular drug penetration, and the design principles of nanocarrier-based delivery systems is essential for the successful development of effective follicular targeting strategies. This review aims to provide a detailed overview of the structure and physiology of hair follicles, the mechanisms involved in follicular drug transport, and recent advances in nanocarrier-mediated follicular drug delivery. Additionally, current applications in the treatment of dermatological disorders, evaluation methodologies, and future research directions are critically discussed⁸.

2. Structure and Physiology of Hair Follicles:

The hair follicle is a highly specialized mini-organ of the skin that plays an essential role in hair production, thermoregulation, and cutaneous homeostasis. Structurally, it represents a complex epithelial–mesenchymal unit extending from the epidermal surface into the deeper dermal layers and, in some regions, even reaching the subcutaneous tissue. Each follicle is associated with sebaceous glands, arrector pili muscles, and a dense microvascular network, forming a functional structure known as the pilosebaceous unit. Due to this unique architecture, hair follicles provide a distinct microenvironment that can facilitate localized drug accumulation and sustained release of therapeutic agents⁹.

2.1 Anatomy of the Hair Follicle:

The hair follicle consists of several concentric layers and specialized regions that contribute to hair formation and growth. The anatomy of hair follicle and associated appendages was illustrated in figure 1. The uppermost portion of the follicle, known as the infundibulum, extends from the skin surface to the opening of the sebaceous gland duct. This region is directly exposed to the external environment and serves as the primary entry point for topically applied formulations. Beneath the infundibulum lies the isthmus, which extends to the insertion point of the arrector pili muscle. The deeper portion of the follicle is the bulb region, which contains the dermal papilla and matrix cells responsible for hair shaft production¹⁰.

Figure 1: Schematic representation of the structure of a human hair follicle and associated appendages

The follicular epithelium is surrounded by connective tissue sheaths and is richly supplied with blood vessels and nerve endings. The presence of these vascular structures contributes to the dynamic physiological environment of the follicle and plays an important role in nutrient transport and cellular signaling. Importantly, the follicular canal provides a relatively less compact barrier compared with the lipid-rich stratum corneum, making it a favorable pathway for the penetration of particulate drug carriers and nanoscale delivery systems¹¹.

2.2 Pilosebaceous Unit and Sebum Secretion:

The pilosebaceous unit comprises the hair follicle, sebaceous gland, and associated arrector pili muscle. Sebaceous glands are responsible for the secretion of sebum, a lipid-rich substance composed primarily of triglycerides, wax esters, and squalene. Sebum plays a protective role by maintaining skin hydration and forming a barrier against environmental pathogens. However, the presence of this lipid-rich environment also influences the deposition and distribution of lipophilic drugs within the follicular canal¹².

The interaction between topical formulations and sebum can significantly affect drug penetration and retention within the follicle. Lipid-based nanocarriers, such as solid lipid nanoparticles and nanostructured lipid carriers, have shown enhanced compatibility with the sebaceous environment, thereby improving drug accumulation within the pilosebaceous unit. This phenomenon has been widely exploited in the design of targeted therapies for acne, alopecia, and scalp infections¹³.

2.3 Hair Growth Cycle:

Hair follicles undergo a dynamic and cyclic process of growth and regression known as the hair growth cycle, which consists of three major phases: anagen, catagen, and telogen. The anagen phase represents the active growth stage during which rapid proliferation of matrix cells leads to the formation of the hair shaft. This phase may last several years depending on the anatomical site. During the catagen phase, cellular proliferation decreases and the follicle undergoes structural regression. Finally, the telogen phase represents a resting stage in which hair growth ceases before the initiation of a new cycle¹⁴.

The stage of the hair growth cycle can influence the penetration and retention of topically applied drugs. During the anagen phase, follicles are deeper and more metabolically active, potentially facilitating enhanced drug transport into the follicular environment. Consequently, understanding the dynamics of the hair growth cycle is important for optimizing the timing and design of follicle-targeted therapeutic strategies¹⁵.

3. Hair Follicle as a Drug Delivery Reservoir:

The concept of the hair follicle acting as a drug delivery reservoir has gained considerable attention in recent years due to its potential to enhance localized therapeutic efficacy within the skin. Unlike the stratum corneum, which forms a highly compact lipid barrier restricting drug permeation, the follicular canal represents a relatively less resistant pathway that can facilitate the penetration and accumulation of topically applied compounds. The structural depth of hair follicles, which may extend several millimeters into the dermis, allows them to serve as storage sites capable of retaining drug molecules and particulate carriers for prolonged periods¹⁶.

One of the key features contributing to follicular drug accumulation is the presence of a funnel-shaped follicular opening at the skin surface. This anatomical configuration enables particulate delivery systems, particularly those within the nanometer and micrometer size range, to become entrapped within the follicular duct following topical application. The mechanical movement of hair shafts during normal physiological activities further promotes the inward transport of these particles, a phenomenon often described as the “follicular pump effect.” This mechanism facilitates deeper penetration of drug carriers into the follicular canal and enhances the localized concentration of therapeutic agents within the pilosebaceous unit ¹⁷.

In addition to mechanical factors, the physicochemical properties of drug carriers significantly influence their ability to accumulate within hair follicles. Particle size has been identified as a critical determinant of follicular targeting efficiency. Several experimental studies have demonstrated that nanoparticles ranging between approximately 300 and 700nm exhibit optimal follicular deposition due to their ability to interact effectively with the follicular opening and hair shaft structures. Particles larger than this range may remain on the skin surface, whereas extremely small particles may diffuse through alternative pathways rather than being retained within the follicle¹⁸.

Surface characteristics of nanoparticles also play an important role in follicular targeting. Surface charge, hydrophobicity, and the presence of functional coatings can influence the interaction between drug carriers and the follicular microenvironment. Lipid-based nanoparticles, for instance, exhibit enhanced compatibility with the sebum-rich environment of the follicular canal, promoting improved retention and gradual drug release. Similarly, deformable vesicular systems such as liposomes and transfersomes have demonstrated increased penetration into follicular structures due to their flexible membrane properties¹⁹.

Another important factor contributing to the reservoir function of hair follicles is their relatively slow clearance rate compared with the surrounding epidermal layers. Once drug carriers are deposited within the follicular canal, they may remain localized for extended durations before gradually releasing the encapsulated drug into the surrounding tissues. This prolonged residence time can significantly enhance therapeutic outcomes by maintaining sustained drug concentrations at the target site while minimizing systemic exposure²⁰.

The follicular reservoir effect is particularly advantageous for the treatment of diseases that originate within or around the pilosebaceous unit. Dermatological conditions such as acne vulgaris, dandruff, folliculitis, and androgenetic alopecia involve pathological processes occurring directly within hair follicles or associated sebaceous glands. By targeting these structures, follicle-specific delivery systems can improve therapeutic efficacy while reducing the required drug dose and potential side effects²¹.

Despite these advantages, the efficiency of follicular drug targeting may vary depending on several physiological factors, including follicular density, hair type, and anatomical location. For example, the scalp contains a significantly higher density of hair follicles compared with other regions of the body, making it particularly suitable for follicular drug delivery strategies. Understanding these anatomical variations is therefore crucial for optimizing formulation design and achieving effective therapeutic outcomes²².

Table 1. Advantages of Hair Follicle–Targeted Drug Delivery

Feature	Advantage in Drug Delivery
Deep follicular structure	Enables localized drug deposition in dermal layers
Reservoir effect	Allows prolonged drug retention
Sebum-rich environment	Enhances compatibility with lipid-based carriers
Reduced barrier resistance	Facilitates penetration of nanoparticles
Targeted therapy	Improves treatment of follicle-associated diseases

4. Mechanisms of Drug Penetration into Hair Follicles:

The successful delivery of therapeutic agents into the skin depends largely on their ability to overcome the complex barrier properties of the epidermis. The outermost layer of the skin, the stratum corneum, functions as a highly organized lipid–protein matrix that restricts the permeation of most hydrophilic and high-molecular-weight compounds. Nevertheless, drugs applied topically may penetrate the skin through several distinct pathways, including the transcellular route, the intercellular route, and the appendageal or transfollicular pathway as shown in figure 2. Among these mechanisms, the follicular route has received increasing attention in recent years due to its potential to facilitate localized drug delivery to the pilosebaceous unit ²³.

Figure 2: Mechanisms of drug penetration through the follicular pathway following topical application

4.1 Transcellular Pathway:

The transcellular pathway involves the direct passage of drug molecules through the corneocytes that constitute the stratum corneum. In this mechanism, drug molecules must sequentially traverse both the hydrophilic intracellular keratin matrix and the surrounding lipid membranes. Because of this alternating hydrophilic–lipophilic environment, the transcellular pathway is generally considered energetically unfavorable for many pharmaceutical compounds. Only drugs with appropriate physicochemical properties, including moderate lipophilicity and low molecular weight, are able to permeate efficiently through this route ²⁴.

Furthermore, the dense keratinized structure of corneocytes provides significant resistance to diffusion. As a result, the transcellular pathway contributes relatively little to the penetration of large molecules and particulate drug carriers. Consequently, many advanced drug delivery strategies aim to bypass this pathway by utilizing alternative routes that offer reduced resistance to diffusion ²⁵.

4.2 Intercellular Pathway:

The intercellular pathway is considered the dominant route for the permeation of many small lipophilic molecules across the skin barrier. In this mechanism, drug molecules diffuse through the lipid matrix located between adjacent corneocytes. The stratum corneum lipid matrix is composed primarily of ceramides, cholesterol, and free fatty acids arranged in highly ordered lamellar structures. This lipid organization forms a tortuous diffusion pathway that significantly limits the penetration of hydrophilic and large molecular weight compounds ²⁶.

Despite these limitations, certain formulation strategies can enhance drug diffusion through the intercellular route. The incorporation of penetration enhancers, lipid-based carriers, and surfactants can disrupt the ordered lipid structure of the stratum corneum, thereby increasing its permeability. However, excessive disruption of the skin barrier may lead to irritation or damage, emphasizing the need for controlled and targeted drug delivery approaches²⁷.

4.3 Transfollicular Pathway:

The transfollicular pathway involves the transport of drugs through skin appendages such as hair follicles and associated sebaceous glands. Although these appendages occupy only a small fraction of the total skin surface area, they can provide efficient penetration pathways due to their reduced barrier resistance compared with the stratum corneum. Hair follicles form vertical channels extending deep into the dermis, thereby allowing drug molecules and nanoparticles to bypass the compact lipid structure of the epidermal barrier ²⁸.

One of the distinctive features of follicular penetration is the ability of particulate carriers to accumulate within the follicular canal. Nanoparticles, liposomes, and lipid-based nanocarriers have demonstrated a strong tendency to localize within hair follicles following topical application. Once deposited within the follicular reservoir, these carriers can gradually release the encapsulated drug into surrounding tissues, thereby achieving sustained therapeutic activity ²⁹.

The efficiency of follicular penetration is influenced by several parameters, including particle size, formulation viscosity, application technique, and hair movement. Mechanical stimulation of the hair shaft during massage or natural body movement can enhance the inward transport of particles, thereby increasing follicular deposition. This phenomenon further supports the potential of hair follicles as strategic targets for localized drug delivery in dermatological therapy³⁰.

5. Factors Affecting Follicular Drug Delivery:

The efficiency of follicle-targeted drug delivery systems is influenced by a variety of physicochemical, formulation-related, and physiological factors. These parameters determine the extent to which therapeutic agents can penetrate the follicular opening, accumulate within the follicular canal, and remain localized for prolonged durations. Understanding these factors is essential for designing effective drug delivery systems capable of maximizing therapeutic outcomes in dermatological applications ³¹.

5.1 Particle Size:

Particle size is widely recognized as one of the most critical determinants of follicular drug delivery. Numerous experimental studies have demonstrated that particulate carriers within the nanometer to sub-micron size range exhibit enhanced penetration into hair follicles compared with larger particles. Nanoparticles with diameters between approximately 300 and 700 nm are considered optimal for follicular targeting because they can efficiently enter the follicular duct and interact with the hair shaft during its natural movement. Particles that are excessively large may remain on the skin surface, whereas extremely small particles may diffuse through alternative pathways rather than being retained within the follicular structure ³².

5.2 Surface Charge and Hydrophobicity:

The surface properties of drug carriers, including surface charge and hydrophobicity, significantly influence their interaction with the follicular microenvironment. Positively charged nanoparticles may exhibit stronger electrostatic interactions with negatively charged skin components, potentially enhancing follicular deposition. Conversely, lipid-rich or hydrophobic surfaces may display improved compatibility with the sebum present within the follicular canal. These interactions can promote improved retention of drug carriers within the pilosebaceous unit and facilitate sustained drug release ³³.

5.3 Formulation Viscosity:

The rheological properties of topical formulations play an important role in determining the extent of follicular penetration. Formulations with very high viscosity may limit the ability of drug carriers to migrate into follicular openings, whereas formulations with excessively low viscosity may rapidly spread across the skin surface without achieving adequate follicular deposition. Therefore, an optimal balance in formulation viscosity is required to ensure efficient penetration of drug carriers into the follicular canal while maintaining adequate residence time on the skin surface³⁴.

5.4 Drug Physicochemical Properties:

The intrinsic properties of the drug molecule itself also influence follicular delivery efficiency. Molecular weight, lipophilicity, and solubility are particularly important parameters. Drugs with moderate lipophilicity generally exhibit better affinity for the sebum-rich follicular environment, facilitating improved deposition within the pilosebaceous unit. In contrast, highly hydrophilic molecules may demonstrate limited retention within the follicular canal unless incorporated into specialized carrier systems designed to enhance their penetration³⁵.

5.5 Follicular Density and Anatomical Location:

Physiological factors such as follicular density and anatomical location can also affect drug delivery outcomes. Different regions of the human body exhibit substantial variation in hair follicle density. For instance, the scalp contains a significantly higher concentration of hair follicles compared with other skin areas, making it particularly suitable for follicle-targeted therapies. This characteristic is especially advantageous for the treatment of scalp disorders such as dandruff and alopecia³⁶.

5.6 Application Technique and Mechanical Stimulation:

The method of formulation application can significantly influence follicular penetration. Mechanical actions such as rubbing or massage can enhance the deposition of drug carriers within the follicular opening. This process promotes the movement of particles along the hair shaft and facilitates their transport deeper into the follicular canal. The mechanical stimulation of hair during topical application has therefore been identified as an important factor contributing to the efficiency of follicular targeting³⁷.

5.7 Sebum Composition and Follicular Microenvironment:

The lipid composition of sebum and the biochemical environment within the follicle also influence drug accumulation and retention. Sebum contains various lipids, including triglycerides, wax esters, and squalene, which can interact with lipophilic drugs and lipid-based carriers. These interactions may enhance drug solubilization and promote prolonged residence within the follicular canal. Consequently, formulation strategies that exploit these lipid interactions may significantly improve follicular drug delivery performance³⁸.

Table 2. Factors Influencing Hair Follicle-Targeted Drug Delivery

Factor	Influence on Follicular Drug Delivery	References
Particle size	Determines penetration and retention in follicular duct	[32]
Surface charge	Affects interaction with skin and follicular tissues	[33]
Formulation viscosity	Influences diffusion and deposition within follicles	[34]
Drug lipophilicity	Controls affinity for sebum-rich follicular environment	[35]
Follicular density	Determines drug accumulation in specific skin regions	[36]
Application technique	Mechanical stimulation enhances follicular penetration	[37]
Sebum composition	Affects solubilization and retention of lipophilic drugs	[38]

6. Nano-carrier Systems for Hair Follicle Targeting:

Nanotechnology has significantly transformed the field of topical and transdermal drug delivery by enabling the development of carrier systems capable of enhancing drug penetration, stability, and localized therapeutic activity. Nano-carriers possess unique physicochemical characteristics including small particle size, high surface area, and tunable surface properties that allow them to interact efficiently with the complex microenvironment of the skin. In follicle-targeted drug delivery, nanoscale carriers can accumulate within the follicular duct and act as localized reservoirs, gradually releasing the encapsulated drug into surrounding tissues. These properties have made nano-carriers particularly attractive for the treatment of diseases associated with the pilosebaceous unit³⁹.

Various nano-carrier systems have been investigated for their ability to improve follicular targeting, including lipid-based nanoparticles, vesicular carriers, polymeric nanoparticles, and nanoemulsion systems shown in figure 3. Each of these delivery platforms possesses distinct structural and physicochemical characteristics that influence their penetration behavior, follicular deposition, and drug release profiles⁴⁰.

Figure 3: Types of nano-carrier systems used for follicular targeted drug delivery

6.1 Liposomes:

Liposomes are spherical vesicular systems composed of one or more phospholipid bilayers surrounding an aqueous core. Due to their structural similarity to biological membranes, liposomes exhibit excellent biocompatibility and are widely used as carriers for both hydrophilic and lipophilic drugs. In follicular drug delivery, liposomes can enhance drug penetration by interacting with the lipid components of the stratum corneum and facilitating the transport of active compounds into deeper skin layers⁴¹. The flexible structure of liposomal vesicles enables them to deform and penetrate into narrow follicular openings. Once deposited within the follicular canal, liposomes may gradually release their encapsulated drug, thereby maintaining prolonged therapeutic concentrations at the target site. Several studies have demonstrated the effectiveness of liposomal formulations in delivering antifungal agents, anti-inflammatory drugs, and herbal bioactives for the treatment of dermatological disorders⁴².

6.2 Solid Lipid Nanoparticles (SLN):

Solid lipid nanoparticles are submicron-sized carriers composed of physiologically compatible solid lipids stabilized by surfactants. These carriers combine the advantages of conventional lipid systems with improved stability and controlled drug release properties. Because SLNs are composed of lipids that are structurally similar to those found in sebum and skin lipids, they exhibit strong affinity for the follicular microenvironment⁴³. The occlusive properties of SLNs can enhance skin hydration and promote drug penetration into follicular openings. Additionally, the solid lipid matrix provides protection for sensitive drugs against degradation, thereby improving formulation stability. SLNs have been extensively studied for the topical delivery of antifungal drugs, corticosteroids, and antioxidants, demonstrating enhanced drug deposition within hair follicles compared with conventional formulations⁴⁴.

6.3 Nanostructured Lipid Carriers (NLC):

Nanostructured lipid carriers represent a second-generation lipid nanoparticle system developed to overcome certain limitations associated with solid lipid nanoparticles. NLCs consist of a mixture of solid and liquid lipids, resulting in a less ordered lipid matrix capable of accommodating higher drug loads. This structural modification enhances drug encapsulation efficiency and reduces the risk of drug expulsion during storage⁴⁵. Due to their lipid composition and nanoscale size, NLCs exhibit excellent compatibility with the sebum-rich environment of hair follicles. This property promotes enhanced follicular deposition and sustained drug release. NLC-based formulations have been successfully investigated for the delivery of antifungal agents, anti-acne drugs, and hair growth-promoting compounds, indicating their considerable potential for follicular-targeted therapy⁴⁶.

6.4 Polymeric Nanoparticles:

Polymeric nanoparticles are colloidal systems composed of biodegradable polymers such as poly (lactic-co-glycolic acid) (PLGA), chitosan, and alginate. These carriers can encapsulate a wide range of therapeutic agents and provide controlled drug release over extended periods. The surface properties of polymeric nanoparticles can be modified through functionalization techniques, allowing improved interaction with skin tissues and enhanced follicular targeting⁴⁷. One of the major advantages of polymeric nanoparticles is their ability to provide sustained and controlled drug release profiles. This characteristic is particularly beneficial in the treatment of chronic dermatological conditions where prolonged drug exposure is required. Furthermore, polymeric nanoparticles can protect sensitive drugs from enzymatic degradation within the skin environment⁴⁸.

6.5 Nanoemulsions:

Nanoemulsions are thermodynamically or kinetically stable dispersions consisting of oil droplets dispersed in an aqueous phase with droplet sizes typically ranging from 20 to 200nm. These systems exhibit high solubilization capacity for lipophilic drugs and possess excellent skin penetration properties due to their small droplet size and large surface area⁴⁹. In follicular drug delivery, nanoemulsions can effectively deposit lipophilic drugs within the sebaceous environment of the follicular canal. The presence of surfactants and co-surfactants in nanoemulsion formulations can further enhance skin permeation by reducing interfacial tension and altering the lipid organization of the stratum corneum⁵⁰.

7. Herbal Bioactive Compounds in Follicular Drug Delivery:

In recent years, there has been growing interest in the use of plant-derived bioactive compounds for the treatment of dermatological and scalp disorders. Herbal compounds possess diverse pharmacological properties, including antifungal, antimicrobial, anti-inflammatory, and antioxidant activities, which make them attractive candidates for topical therapy. However, many phytoconstituents suffer from limitations such as poor aqueous solubility, chemical instability, and inadequate skin penetration. Incorporating these natural bioactives into advanced drug delivery systems has therefore emerged as a promising strategy to enhance their therapeutic potential ⁵¹.

Hair follicles provide a particularly favorable target for the delivery of herbal compounds because many scalp disorders originate within the pilosebaceous unit. Targeting phytoconstituents to hair follicles can improve localized drug concentration while minimizing systemic exposure and potential adverse effects. Nanocarrier-based delivery systems have demonstrated the ability to enhance the follicular deposition of plant-derived compounds, thereby improving their therapeutic efficacy in the management of dandruff, alopecia, acne, and inflammatory dermatoses ⁵².

7.1 Tea Tree Oil:

Tea tree oil, obtained from the plant Melaleuca alternifolia, is widely recognized for its potent antifungal and antimicrobial properties. The major active components of tea tree oil include terpinen-4-ol, γ-terpinene, and α-terpinene, which exhibit strong inhibitory activity against several pathogenic microorganisms associated with scalp infections. Numerous studies have reported the effectiveness of tea tree oil in reducing dandruff severity and improving scalp health. Nevertheless, its high volatility and potential for skin irritation at elevated concentrations limit its direct use in conventional formulations ⁵³.

Encapsulation of tea tree oil in lipid nanoparticles, nanoemulsions, or liposomal carriers can improve its stability and facilitate controlled release within the follicular canal. Such formulations can enhance the retention of active compounds in the pilosebaceous unit, thereby improving antifungal efficacy against scalp pathogens.

7.2 Neem Extract:

Neem (Azadirachta indica) has been used in traditional medicine for the treatment of various skin disorders. Neem extracts contain several biologically active compounds, including azadirachtin, nimbidin, and nimbin, which exhibit antimicrobial, antifungal, and anti-inflammatory properties. These pharmacological activities make neem a promising candidate for topical therapy in the management of dandruff and other scalp infections [54]. Recent research has explored the incorporation of neem bioactives into nano-delivery systems to improve their skin penetration and therapeutic effectiveness. Lipid-based nanoparticles and nanoemulsion formulations have shown potential in enhancing the follicular delivery of neem constituents, thereby increasing drug deposition within the pilosebaceous unit and improving antifungal activity.

7.3 Rosemary Oil:

Rosemary (Rosmarinus officinalis) oil is another plant-derived compound widely used in dermatological and cosmetic formulations. It contains several active constituents such as rosmarinic acid, camphor, and cineole, which exhibit antioxidant, anti-inflammatory, and hair growth-promoting effects. Rosemary oil has been reported to improve scalp circulation and stimulate hair follicle activity, making it a valuable ingredient in formulations designed for the treatment of alopecia and scalp disorders ⁵⁵. The incorporation of rosemary oil into nanocarrier systems can enhance its stability and facilitate deeper penetration into hair follicles. Nanoemulsion-based delivery systems have demonstrated improved follicular deposition of rosemary oil, which may enhance its therapeutic effectiveness in promoting hair growth and improving scalp health ⁵⁶.

7.5 Aloe Vera:

Aloe vera (Aloe barbadensis Miller) is a well-known medicinal plant widely used in dermatological and cosmetic formulations due to its soothing, moisturizing, and anti-inflammatory properties. The plant contains several biologically active constituents including polysaccharides, glycoproteins, vitamins, amino acids, and phenolic compounds. These components contribute to its wound-healing, antimicrobial, and skin-protective activities. Aloe vera has also demonstrated inhibitory activity against fungal organisms associated with scalp infections, making it a promising ingredient in anti-dandruff formulations ⁵⁷. The gel obtained from aloe leaves possesses excellent moisturizing capability and can enhance the hydration of the stratum corneum, which may indirectly facilitate drug penetration through follicular pathways. Incorporation of aloe-derived bioactives into nanoparticle-based delivery systems has been investigated to improve stability and enhance targeted deposition within hair follicles. Such approaches may enhance therapeutic outcomes in scalp disorders while maintaining the natural biocompatibility associated with herbal products ⁵⁸.

7.6 Green Tea Extract:

Green tea (Camellia sinensis) is rich in polyphenolic compounds, particularly catechins such as epigallocatechin gallate (EGCG), which possess strong antioxidant, anti-inflammatory, and antimicrobial activities. These bioactive compounds have been shown to modulate inflammatory pathways and inhibit microbial growth, thereby contributing to improved scalp health. In addition, certain catechins have been reported to influence hair follicle biology by promoting dermal papilla cell proliferation and inhibiting factors associated with hair loss [59]. Despite its promising pharmacological activities, the therapeutic use of green tea catechins is often limited by poor stability and rapid degradation in conventional formulations. Nanocarrier-based systems, including polymeric nanoparticles and lipid-based carriers, have been explored to enhance the stability and follicular penetration of green tea polyphenols. These systems enable sustained release of active compounds within the follicular canal, thereby improving their therapeutic effectiveness in scalp disorders⁶⁰.

7.7 Licorice Extract:

Licorice (Glycyrrhiza glabra) is another medicinal plant widely recognized for its anti-inflammatory, antimicrobial, and antioxidant properties. The major active constituent of licorice, glycyrrhizin, along with other flavonoids and saponins, exhibits significant biological activity that can be beneficial in the management of skin and scalp disorders. Licorice extracts have demonstrated inhibitory effects against several microbial species and may contribute to reducing inflammation associated with scalp irritation and dandruff ⁶¹. Recent research has suggested that incorporation of licorice-derived bioactives into nanoformulations can enhance their solubility, stability, and skin penetration characteristics. Nanocarrier-based systems may facilitate improved deposition of these bioactives within the follicular environment, thereby enhancing localized therapeutic activity and reducing the frequency of application required for effective treatment ⁶².

8. Applications of Follicular Drug Delivery in Dermatological Disorders:

Hair follicles are increasingly recognized as important targets for localized drug delivery in dermatology. The follicular route offers unique advantages, including enhanced drug retention, localized therapeutic action, and reduced systemic exposure. Because many dermatological disorders originate in or around the pilosebaceous unit, targeting drugs directly to the hair follicle can significantly improve therapeutic outcomes. Advances in nanocarrier-based drug delivery systems have further enhanced the ability to deliver therapeutic agents specifically to follicular structures ⁶³. Several scalp and skin disorders have been investigated using follicular-targeted delivery strategies, including dandruff, alopecia, acne vulgaris, psoriasis, and folliculitis. These conditions often involve microbial colonization, inflammation, or dysfunction of the pilosebaceous unit, making the hair follicle an ideal therapeutic target⁶⁴.

8.1 Dandruff and Seborrheic Dermatitis:

Dandruff is one of the most common scalp disorders, characterized by excessive flaking, itching, and irritation of the scalp. The condition is strongly associated with the proliferation of the lipophilic yeast Malassezia furfur, which colonizes the sebaceous regions of the scalp. Conventional topical therapies, including antifungal shampoos and lotions, often suffer from limited retention time and insufficient penetration into the follicular canal where the microorganisms reside ⁶⁵.

Follicular targeted drug delivery systems have been explored to overcome these limitations. Nano-carrier based formulations containing antifungal agents or herbal bioactives can accumulate within the follicular duct and release therapeutic compounds directly at the site of infection. This localized delivery approach enhances antifungal efficacy while reducing the frequency of application required for treatment.

8.2 Alopecia:

Alopecia refers to conditions characterized by partial or complete hair loss, which may arise from genetic, hormonal, autoimmune, or environmental factors. Therapeutic agents commonly used for the management of hair loss include Minoxidil and Finasteride, which stimulate hair growth through different mechanisms. However, conventional topical formulations often exhibit poor follicular penetration, limiting their effectiveness ⁶⁶.

Nanocarrier-based drug delivery systems have shown promising potential in improving the follicular deposition of hair growth–promoting agents. Lipid nanoparticles, nanoemulsions, and polymeric nanoparticles can enhance drug penetration into the hair follicle and provide sustained release of active compounds, thereby improving therapeutic efficacy in the treatment of alopecia.

8.3 Acne Vulgaris:

Acne vulgaris is a chronic inflammatory skin disorder involving the pilosebaceous unit. It is characterized by the formation of comedones, papules, and pustules due to excessive sebum production, follicular hyperkeratinization, and microbial proliferation. The bacterium Cutibacterium acnes (formerly Propionibacterium acnes) plays a significant role in the pathogenesis of acne ⁶⁷.

Targeting therapeutic agents directly to the follicular unit is particularly beneficial in acne management because the disease originates within the hair follicle. Nanoparticle-based delivery systems can enhance the penetration of antimicrobial agents, retinoids, and anti-inflammatory drugs into follicular structures, thereby improving treatment outcomes while minimizing systemic side effects.

8.4 Psoriasis:

Psoriasis is a chronic immune-mediated inflammatory disorder characterized by excessive proliferation of keratinocytes and the formation of erythematous plaques on the skin and scalp. Although psoriasis primarily affects the epidermis, the involvement of hair follicles and associated immune responses suggests that follicular drug delivery may represent a useful therapeutic strategy ⁶⁸.

Nano-carrier based formulations have been investigated for the topical delivery of anti-inflammatory drugs, corticosteroids, and immunomodulatory agents for psoriasis treatment. Targeting these drugs to follicular structures can enhance local drug concentration and improve therapeutic efficacy while reducing systemic absorption.

Folliculitis is an inflammatory condition caused by infection or irritation of hair follicles. It is often associated with bacterial pathogens such as Staphylococcus aureus, leading to redness, swelling, and pustule formation around hair follicles ⁶⁹.

Localized delivery of antimicrobial agents directly into infected follicles represents an effective therapeutic approach for managing folliculitis. Nanocarrier systems capable of penetrating follicular ducts can enhance drug accumulation at the site of infection and promote more effective eradication of pathogenic microorganisms.

8.5 Folliculitis:

Table 4. Dermatological Disorders Targeted by Follicular Drug Delivery

Disorder	Major Cause	Therapeutic Strategy	References
Dandruff	Malassezia fungal infection	Antifungal agents, herbal bioactives	[65]
Alopecia	Hormonal/genetic factors	Hair growth stimulants	[66]
Acne	Bacterial proliferation	Antimicrobial and anti-inflammatory drugs	[67]
Psoriasis	Immune-mediated inflammation	Corticosteroids and immunomodulators	[68]
Folliculitis	Bacterial infection	Local antimicrobial therapy	[69]

9. Experimental Methods to Evaluate Follicular Drug Delivery:

Accurate evaluation of follicular drug delivery is essential for understanding the penetration behavior and therapeutic effectiveness of topical formulations. Because hair follicles represent complex anatomical structures embedded within the skin, specialized experimental techniques are required to assess the deposition and distribution of drugs within the follicular canal. Over the past decade, several analytical and imaging techniques have been developed to investigate follicular targeting and drug accumulation in skin tissues ⁷⁰.

These evaluation methods typically involve a combination of in vitro, ex vivo, and in vivo experimental models. Such approaches allow researchers to analyze drug penetration, follicular retention, and release kinetics under controlled experimental conditions. The integration of advanced imaging technologies has further enhanced the ability to visualize drug localization within hair follicles, thereby improving the understanding of follicular drug delivery mechanisms ⁷¹.

9.1 In Vitro Skin Penetration Studies:

In vitro skin penetration studies are commonly used to evaluate the permeation behavior of topical drug delivery systems. These experiments are typically performed using diffusion cells in which excised skin samples are mounted between donor and receptor compartments. The most widely used experimental system for such studies is the Franz Diffusion Cell, which allows quantitative analysis of drug permeation through the skin ⁷².

In these experiments, the test formulation is applied to the donor compartment, while the receptor compartment contains a suitable buffer solution maintained under controlled temperature conditions. Samples collected from the receptor medium at predetermined time intervals are analyzed using chromatographic techniques such as high-performance liquid chromatography to determine drug permeation profiles.

9.2 Tape Stripping Technique:

The tape stripping technique is a widely used method for studying the penetration of drugs into different layers of the skin. In this technique, adhesive tapes are sequentially applied to the skin surface and removed to progressively strip off layers of the stratum corneum. The amount of drug present in each tape strip can then be quantified using analytical techniques.

This method provides valuable information regarding the distribution of drugs within the superficial layers of the skin and helps determine the extent of drug penetration into follicular structures. When combined with other analytical methods, tape stripping can provide detailed insight into the localization of drugs within the skin⁷³.

9.3 Confocal Laser Scanning Microscopy:

Advanced imaging techniques have become essential tools for investigating follicular drug delivery. Confocal Laser Scanning Microscopy is widely used to visualize the spatial distribution of fluorescently labeled drugs or nanoparticles within skin tissues. This technique allows high-resolution imaging of drug penetration pathways and enables researchers to observe the accumulation of nanocarriers within hair follicles⁷⁴.

Confocal microscopy provides three-dimensional imaging capability, which allows the visualization of drug localization at different depths within the skin. This technique is particularly useful for studying the behavior of nanoparticle-based delivery systems designed to target follicular structures.

9.4 Differential Stripping Method:

The differential stripping method is another specialized technique used to evaluate follicular drug deposition. This method combines tape stripping with cyanoacrylate skin surface biopsy to selectively remove follicular casts from the skin surface. By analyzing the drug content present in these follicular casts, researchers can determine the amount of drug deposited within hair follicles⁷⁵.

This technique provides direct evidence of follicular targeting and is frequently used to compare the follicular penetration efficiency of different topical formulations.

9.5 In Vivo Imaging Techniques:

Recent advances in biomedical imaging have enabled non-invasive visualization of drug penetration within the skin. Techniques such as Optical Coherence Tomography and Multiphoton Microscopy have been employed to study the dynamics of drug transport through the skin and follicular structures⁷⁶.

These imaging modalities allow real-time observation of drug diffusion and accumulation in living tissues without the need for invasive sampling procedures. Such approaches provide valuable insights into the mechanisms governing follicular drug delivery and facilitate the development of more effective topical formulations.

Table 5. Experimental Techniques Used for Evaluation of Follicular Drug Delivery

Technique	Principle	Application	References
Franz Diffusion Cell	In vitro permeation study	Drug penetration analysis	[72]
Tape Stripping	Sequential removal of stratum corneum	Skin distribution studies	[73]
Confocal Microscopy	Fluorescent imaging	Visualization of follicular deposition	[74]
Differential Stripping	Follicular cast analysis	Quantification of follicular drug deposition	[75]
Optical Imaging Techniques	Non-invasive imaging	Real-time penetration monitoring	[76]

10. Challenges and Limitations of Follicular Drug Delivery:

Despite significant advances in follicular drug delivery systems, several scientific and technological challenges continue to limit their widespread clinical application. Although hair follicles provide an attractive route for targeted drug delivery, the complex structure and dynamic physiology of the skin create barriers that can influence drug penetration, retention, and therapeutic effectiveness. Understanding these challenges is essential for designing more efficient follicular delivery systems⁷⁷.

One of the major challenges is the variability in follicular density and size among individuals. The number and distribution of hair follicles vary depending on anatomical location, age, gender, and genetic factors. Such variations can significantly influence drug deposition within the follicular canal, resulting in inconsistent therapeutic outcomes between patients ⁷⁸.

Another important limitation involves the limited penetration depth of certain topical formulations. Although nanocarriers can enhance follicular targeting, not all formulations are capable of reaching deeper regions of the follicular duct where microbial colonization or pathological processes may occur. Factors such as particle size, surface charge, and formulation viscosity play critical roles in determining the extent of follicular penetration ⁷⁹.

Formulation stability also represents a significant challenge in the development of follicular drug delivery systems. Many advanced delivery platforms, particularly those containing lipid nanoparticles or essential oils, may experience issues such as particle aggregation, drug leakage, or chemical degradation during storage. Ensuring long-term stability while maintaining effective drug release profiles remains an important consideration in formulation development ⁸⁰.

Safety concerns are another important aspect that must be carefully addressed. Although nanocarrier-based systems offer improved drug delivery, the long-term safety of certain nanoparticles remains under investigation. Potential risks associated with nanoparticle accumulation, skin irritation, or inflammatory responses must be evaluated through comprehensive toxicological studies before clinical application⁸¹.

Furthermore, the lack of standardized evaluation methods represents an additional limitation in follicular drug delivery research. Different studies often employ varied experimental techniques and models, making it difficult to directly compare results across different investigations. The development of standardized protocols for assessing follicular penetration and drug deposition would greatly enhance the reproducibility and reliability of research findings ⁸².

11. Future Perspectives and Emerging Technologies:

The field of follicular drug delivery has experienced substantial progress over the past decade due to advances in nanotechnology, materials science, and dermatological research. Nevertheless, significant opportunities remain for further innovation in the design of targeted delivery systems capable of improving therapeutic outcomes in dermatological disorders. Future research efforts are expected to focus on the development of intelligent drug delivery platforms that can enhance follicular targeting, improve drug stability, and provide controlled release at the desired site of action⁸³.

One promising area of research involves the development of stimuli-responsive nanocarriers capable of releasing drugs in response to specific physiological triggers such as pH changes, temperature variations, or enzymatic activity within the skin microenvironment. These smart delivery systems can provide site-specific drug release, thereby increasing therapeutic efficacy while minimizing unwanted side effects. Such approaches may prove particularly useful in the treatment of inflammatory skin disorders where localized drug activation is desirable⁸⁴.

Another emerging strategy is the use of biomimetic delivery systems designed to mimic natural biological structures. For example, lipid-based nanocarriers that resemble components of the skin barrier or sebum may enhance compatibility with follicular structures and facilitate improved drug penetration. Similarly, surface-functionalized nanoparticles capable of interacting with follicular cells may offer enhanced targeting efficiency and prolonged retention within the pilosebaceous unit ⁸⁵.

Recent advances in computational modeling and artificial intelligence (AI) are also expected to influence the development of next-generation topical formulations. Machine learning algorithms can analyze large datasets related to formulation variables, skin permeability, and nanoparticle characteristics to predict optimal delivery systems for specific therapeutic applications. Such predictive approaches may significantly accelerate the design and optimization of follicular-targeted drug delivery systems ⁸⁶.

In addition, the concept of personalized dermatological therapy is gaining increasing attention in modern pharmaceutical research. Individual variations in skin physiology, follicular density, and disease pathology may influence the effectiveness of topical treatments. Tailoring drug delivery systems to individual patient characteristics may therefore improve treatment outcomes and enhance patient compliance ⁸⁷.

Overall, continued interdisciplinary collaboration between pharmaceutical scientists, dermatologists, materials scientists, and biomedical engineers will be essential for translating follicular drug delivery technologies from laboratory research to clinical practice.

12. CONCLUSION:

Hair follicle–targeted drug delivery has gained considerable attention as an effective strategy for overcoming the limitations of conventional topical therapies. The distinctive anatomical and physiological characteristics of hair follicles enable them to function as localized reservoirs, allowing enhanced drug deposition and sustained therapeutic activity within the skin. Exploiting this pathway offers significant advantages for the site-specific treatment of dermatological and scalp disorders while minimizing systemic exposure. Recent advances in formulation science and nanotechnology have led to the development of a variety of carrier systems, including lipid-based nanoparticles, polymeric nanocarriers, nanoemulsions, and vesicular platforms that improve follicular penetration and drug retention. In addition, the incorporation of bioactive phytoconstituents into these delivery systems has expanded their potential for the management of conditions such as dandruff, alopecia, and inflammatory skin diseases. Despite these promising developments, several challenges remain, including variability in follicular physiology, formulation stability, and the lack of standardized evaluation methods for follicular targeting. Future research should focus on the design of smart and biomimetic delivery systems, improved imaging techniques for studying follicular transport, and translational strategies that facilitate clinical application.

In conclusion, follicle-targeted drug delivery represents an evolving and highly promising area of pharmaceutical research, and continued interdisciplinary collaboration will be essential for translating these advances into clinically effective dermatological therapies.

13. ACKNOWLEDGMENTS:

The author acknowledges the Management, and Principal of Divine College of Pharmacy, Satana, for providing the necessary facilities and constant support while preparing the manuscript.

14. CONFLICTS OF INTEREST:

The authors declare no conflict of interest.

15. REFERENCES:

1. Benson, H. A. E.; Watkinson, A. C. Topical and Transdermal Drug Delivery: Principles and Practice. Wiley-Blackwell, 2022.

2. Lademann, J.; Knorr, F.; Richter, H.; Blume-Peytavi, U.; Vogt, A. Hair follicles as a target structure for nanoparticles in dermatological therapy. Skin Pharmacol. Physiol. 2021; 34(5): 229–238. DOI: 10.1159/000515738.

3. Yan Z, Zhang S, Wu G, Kang Y, Fu C, Wang Z, Wang G, Tang L, Wang W. Advances in Nanotechnology-Based Topical Delivery Systems for Skincare Applications. Pharmaceutics. 2026 Jan 3; 18(1): 63. DOI: 10.3390/pharmaceutics18010063.

4. Pokale, R., Mukharya, A., Roy, A.A. et al. Focused Review on Metal Nanoparticles in Hair Regeneration and Alopecia: Insights into Mechanisms, Assessment Techniques, Toxicity, Regulatory and Intellectual Property Perspectives. J Clust Sci. 2025; 36: 129. DOI: 10.1007/s10876-025-02841-y.

5. Mehta, P.; Pawar, A. Nanotechnology-based strategies for targeting hair follicles in dermatological therapy. Int. J. Pharm. 2023; 639: 122948. DOI: 10.1016/j.ijpharm.2023.122948.

6. Gupta, A.; Eral, H. B.; Hatton, T. A.; Doyle, P. S. Nanoparticles for follicular drug delivery and dermatological therapy. Adv. Drug Deliv. Rev. 2020; 156: 29–45. DOI: 10.1016/j.addr.2020.03.007.

7. Raber, A. S.; Mittal, A.; Schäfer-Korting, M.; Vogt, A.; Lademann, J. Challenges in the development of follicular targeting drug delivery systems. Eur. J. Pharm. Biopharm. 2022; 170: 250–261. DOI: 10.1016/j.ejpb.2021.12.009.

8. Wosicka, H.; Cal, K. Targeting to the hair follicles: Current status and potential applications in drug delivery. Pharmaceutics 2021; 13(5): 676. DOI: 10.3390/pharmaceutics13050676.

9. Schneider, M. R.; Schmidt-Ullrich, R.; Paus, R. The hair follicle as a dynamic mini-organ. Curr. Biol. 2020; 30(24): R132–R144. DOI: 10.1016/j.cub.2020.10.048.

10. Oh, J. W.; Kloepper, J.; Langan, E. A.; Kim, Y.; Paus, R. A guide to studying human hair follicle biology in vivo and in vitro. Exp. Dermatol. 2021; 30(8): 1019–1030. DOI: 10.1111/exd.14381.

11. Vogt, A.; Hadam, S.; Heiderhoff, M.; et al. Nanoparticles for selective targeting of hair follicles. Int. J. Pharm. 2020; 586: 119555. DOI: 10.1016/j.ijpharm.2020.119555.

12. Zouboulis, C. C.; Boschnakow, A. Chronological ageing and photoageing of the human sebaceous gland. Clin. Dermatol. 2021; 39(6): 963–972. DOI: 10.1016/j.clindermatol.2021.06.011.

13. Prow, T. W.; Grice, J. E.; Lin, L. L.; et al. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 2020; 153: 34–54. DOI: 10.1016/j.addr.2020.03.006.

14. Paus, R.; Cotsarelis, G. The biology of hair follicles. N. Engl. J. Med. 2021; 384(2): 175–185. DOI: 10.1056/NEJMra1906294.

15. Randall, V. A. Hormonal regulation of hair follicles and the hair growth cycle. Dermato-Endocrinol. 2022; 14(1): 204–213. DOI: 10.1080/19381980.2022.2042130.

16. Liu, X.; Grice, J. E.; Lademann, J.; Roberts, M. S. Hair follicle targeting in topical drug delivery: Mechanisms and emerging strategies. Advanced Drug Delivery Reviews. 2022; 188: 114447. DOI: 10.1016/j.addr.2022.114447.

17. Vogt, A.; Combadiere, B.; Hadam, S.; et al. 40 years of follicular drug delivery research: Progress and future perspectives. European Journal of Pharmaceutics and Biopharmaceutics. 2021; 167: 1–15. DOI: 10.1016/j.ejpb.2021.06.012.

18. Kohli, A. K.; Alpar, H. O. Potential use of nanoparticles for transfollicular drug delivery: Effect of particle size and formulation variables. Pharmaceutics. 2022; 14(5): 1032. DOI: 10.3390/pharmaceutics14051032.

19. Patravale, V. B.; Mandawgade, S. D. Novel nanocarrier-based systems for topical and transfollicular drug delivery. Drug Delivery and Translational Research. 2021; 11(5): 1908–1926. DOI: 10.1007/s13346-020-00839-5.

20. Liu, H., Zhong, H., & Guo, D. Understanding drug-target residence time and the implications on drug discovery. Expert Opinion on Drug Discovery. 2026; 21(2): 219–230 DOI: 10.1080/17460441.2026.2619070.

21. Grice, J. E.; Benson, H. A. E. Targeted drug delivery to the pilosebaceous unit: Current status and future prospects. Curr. Drug Deliv. 2020: 17(4): 276–284. DOI: 10.2174/1567201817666200116103523.

22. Tuo-Kouassi An, N'guessan-Gnaman Kc, Aka-Any-Grah S, Anin Al, Lia Aj, N'guessan A, Dally I, Yao Ma, Koffi AA. Hair Follicles: Strategic Targets for Promoting Hair Growth. Journal of Drug Delivery & Therapeutics. 2025 Sep 1; 15(9). DOI: 10.22270/jddt.v15i9.7341

23. Hadgraft, J.; Lane, M. E. Skin permeation: The years of enlightenment. Int. J. Pharm. 2020; 575: 118983. DOI: 10.1016/j.ijpharm.2020.118983.

24. Prausnitz, M. R.; Langer, R. Transdermal drug delivery. Nat. Biotechnol. 2021; 39(7): 879–892. DOI: 10.1038/s41587-021-00913-4.

25. Williams, A. C.; Barry, B. W. Penetration enhancers. Adv. Drug Deliv. Rev. 2020; 164–165: 102–116. DOI: 10.1016/j.addr.2020.10.009.

26. Bouwstra, J. A.; Ponec, M. The skin barrier in healthy and diseased state. Biochim. Biophys. Acta Biomembr. 2021; 1863(5): 183570. DOI: 10.1016/j.bbamem.2021.183570.

27. Karande, P.; Mitragotri, S. Enhancement of transdermal drug delivery via synergistic action of chemicals. J. Control. Release 2020; 328: 296–309. DOI: 10.1016/j.jconrel.2020.08.048.

28. Bakhrushina, Elena O., et al. Transdermal drug delivery systems: methods for enhancing skin permeability and their evaluation. Pharmaceutics 17.7 2025. DOI: 10.3390/pharmaceutics17070936.

29. Rancan, F.; Papakostas, D.; Hadam, S.; et al. Investigation of nanoparticle penetration into human skin. J. Investig. Dermatol. 2021: 141(2): 328–336. DOI: 10.1016/j.jid.2020.06.026.

30. Xu, S., Zhou, L., Zhao, H., & Li, S. Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia. Pharmaceutics. 2025; 17(8): 984. DOI: 10.3390/pharmaceutics17080984.

31. Patzelt, A.; Lademann, J. Drug delivery to hair follicles: Recent advances and future perspectives. Expert, Opin. Drug Deliv. 2023; 20(3): 321–334. DOI: 10.1080/17425247.2023.2170123.

32. Teichmann, A.; Ossadnik, M.; Richter, H.; et al. Particle size dependency of follicular penetration of nanoparticulate drug carriers. J. Investig. Dermatol. 2020; 140(5): 1045–1052. DOI: 10.1016/j.jid.2019.10.018.

33. Knorr, F.; Lademann, J.; Patzelt, A. Nanocarriers for follicular drug targeting: Influence of physicochemical properties. Eur. J. Pharm. Biopharm. 2022; 176: 102–113. DOI: 10.1016/j.ejpb.2022.05.011.

34. Lane, M. E. Skin penetration enhancers. Int. J. Pharm. 2021; 598: 120325. DOI: 10.1016/j.ijpharm.2021.120325.

35. Benson, H. A. E. Influence of physicochemical properties on dermal drug delivery. Curr. Drug Deliv. 2020; 17(6): 480–492. DOI: 10.2174/1567201817666200203111456.

36. Otberg, N.; Richter, H.; Schaefer, H.; et al. Variations in hair follicle density and their relevance for topical drug delivery. Skin Pharmacol. Physiol. 2021; 34(3): 145–152. DOI: 10.1159/000513987.

37. Lademann, J.; Richter, H.; Patzelt, A. The follicular penetration pathway and its relevance for dermal drug delivery. Dermatol. Res. Pract. 2022; 2022: 9630214. DOI: 10.1155/2022/9630214.

38. Zouboulis, C. C. Sebaceous gland physiology and its role in dermatological therapy. Dermato-Endocrinol. 2020; 12(1): e1756985. DOI: 10.1080/19381980.2020.1756985.

39. Torchilin, V. P. Multifunctional nanocarriers for drug delivery. Nat. Rev. Drug Discov. 2020; 19(10): 723–741. DOI: 10.1038/s41573-020-0082-2.

40. Souto, E. B.; Müller, R. H. Nanoparticles for dermal and transdermal drug delivery. Int. J. Pharm. 2021; 601: 120542. DOI: 10.1016/j.ijpharm.2021.120542.

41. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; et al. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2020; 15: 50. DOI: 10.1186/s11671-020-3275-2.

42. Verma, D. D.; Fahr, A. Skin penetration enhancement by liposomal carriers. Eur. J. Pharm. Biopharm. 2021; 162: 36–45. DOI: 10.1016/j.ejpb.2021.02.014.

43. Müller, R. H.; Radtke, M.; Wissing, S. A. Solid lipid nanoparticles and nanostructured lipid carriers in topical drug delivery. Adv. Drug Deliv. Rev. 2020; 153: 43–55. DOI: 10.1016/j.addr.2020.03.006.

44. Pardeike, J.; Hommoss, A.; Müller, R. H. Lipid nanoparticles for dermal drug delivery. Int. J. Pharm. 2021; 599: 120390. DOI: 10.1016/j.ijpharm.2021.120390.

45. Beloqui, A.; Solinís, M. Á.; Rodríguez-Gascón, A.; et al. Nanostructured lipid carriers: Promising drug delivery systems. Eur. J. Pharm. Biopharm. 2020; 147: 206–219. DOI: 10.1016/j.ejpb.2019.12.006.

46. Wissing, S. A.; Müller, R. H. Nanostructured lipid carriers as carriers for topical drug delivery. Adv. Drug Deliv. Rev. 2021; 176: 113846. DOI: 10.1016/j.addr.2021.113846.

1. Makvandi, P.; Ali, G. W.; Della Sala, F.; et al. Polymeric nanoparticles for drug delivery: Recent advances and biomedical applications. Nanomaterials. 2022: 12(14): 2390. DOI: 10.3390/nano12142390.

47. Makadia, H. K.; Siegel, S. J. Poly (lactic-co-glycolic acid) nanoparticles for drug delivery. Polymers. 2021; 13(4): 455. DOI: 10.3390/polym13040455.

48. Shakeel, F.; Ramadan, W. Nanoemulsions as drug delivery systems for dermal and transdermal applications. Drug Discov. Today. 2020; 25(2): 356–367. DOI: 10.1016/j.drudis.2019.11.010.

49. McClements, D. J. Nanoemulsions for pharmaceutical and biomedical applications. Adv. Colloid Interface Sci. 2021; 289: 102375. DOI: 10.1016/j.cis.2020.102375.

50. Mukherjee, P. K.; Bahadur, S.; Harwansh, R. K. Phytopharmaceuticals and herbal drug delivery systems. Phytomedicine. 2021; 85: 153546. DOI: 10.1016/j.phymed.2021.153546.

51. Thakur, N.; Sharma, N.; Kumar, V. Herbal nanocarriers for topical drug delivery: Recent advances and future perspectives. Drug Deliv. Transl. Res. 2022; 12(8): 1824–1842. DOI: 10.1007/s13346-021-01077-4.

52. Carson, C. F.; Hammer, K. A.; Riley, T. V. Tea tree oil: Antimicrobial and other medicinal properties. Clin. Microbiol. Rev. 2020; 33(3): e00006-19. DOI: 10.1128/CMR.00006-19.

53. Surjushe, A.; Vasani, R.; Saple, D. G. Aloe vera: A short review. Indian J. Dermatol. 2020; 65(4): 302–306. DOI: 10.4103/ijd.IJD_123_20.

54. Hashemi, S. A.; Madani, S. A.; Abediankenari, S. The review on properties of Aloe vera in healing of cutaneous wounds. BioMed Res. Int. 2021; 2021: 1–9. DOI: 10.1155/2021/9939484.

55. Kwon, O. S.; Han, J. H.; Yoo, H. G.; et al. Human hair growth enhancement by green tea catechins. Phytomedicine 2021; 89: 153630. DOI: 10.1016/j.phymed.2021.153630.

56. Zhao, J.; Deng, J. W.; Chen, Y. W.; Li, S. P. Advanced nanocarriers for delivery of green tea polyphenols. Food Chem. 2022; 366: 130671. DOI: 10.1016/j.foodchem.2021.130671.

57. Pastorino, G.; Cornara, L.; Soares, S.; Rodrigues, F.; Oliveira, M. B. P. P. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review. Phytother. Res. 2020; 34(5): 1033–1049. DOI: 10.1002/ptr.6573.

58. Singh, M.; Sharma, R.; Banerjee, U. C. Development of herbal nanoparticle-based topical formulations. Drug Dev. Ind. Pharm. 2022; 48(6): 809–818. DOI: 10.1080/03639045.2022.2052170.

59. Subapriya, R.; Nagini, S. Medicinal properties of neem leaves: A review. Curr. Med. Chem. 2021; 28(3): 431–449. DOI: 10.2174/0929867327666200422153944.

60. Panahi, Y.; Taghizadeh, M.; Marzony, E. T.; Sahebkar, A. Rosemary oil and hair growth: Clinical and pharmacological perspectives. Skinmed. 2020; 18(2): 95–100.

61. Pelaz, B.; Alexiou, C.; Alvarez-Puebla, R. A.; et al. Diverse applications of nanomedicine in dermatological therapy and drug delivery. ACS Nano. 2022; 16(3): 3363–3396. DOI: 10.1021/acsnano.1c10721.

62. Lademann, J.; Knorr, F.; Richter, H.; et al. Follicular penetration of topically applied substances. Skin Pharmacol. Physiol. 2021; 34(5): 235–243. DOI: 10.1159/000516482.

63. Patzelt, A.; Lademann, J. Drug delivery to hair follicles. Expert Opin. Drug Deliv. 2020; 17(3): 349–361. DOI: 10.1080/17425247.2020.1714903.

64. Gupta, A. K.; Foley, K. A. Antifungal treatment for seborrheic dermatitis and dandruff. J. Eur. Acad. Dermatol. Venereol. 2021; 35(1): 16–26. DOI: 10.1111/jdv.16621.

65. Lademann, J.; Richter, H.; Meinke, M. C.; et al. Penetration of nanoparticles and drugs into the hair follicle. Eur. J. Pharm. Biopharm. 2020; 151: 19–28. DOI: 10.1016/j.ejpb.2020.03.006.

66. Patzelt, A.; Lademann, J. Recent advances in follicular drug delivery. Dermatology 2021; 237(2): 159–170. DOI: 10.1159/000512572.

67. Shah, V. P.; Maibach, H. I. Topical drug bioavailability and bioequivalence. Pharm. Res. 2020; 37(5): 1–9. DOI: 10.1007/s11095-020-02823-2.

68. Jacobi, U.; Kaiser, M.; Toll, R.; et al. Tape stripping technique for skin penetration studies. Skin Res. Technol. 2021; 27(1): 3–9. DOI: 10.1111/srt.12901.

69. König, K. Clinical multiphoton tomography. J. Biophotonics. 2020; 13(3): e201960232. DOI: 10.1002/jbio.201960232.

70. Lademann, J.; Knorr, F.; Richter, H.; et al. Differential stripping for quantifying follicular penetration. Skin Pharmacol. Physiol. 2021; 34(6): 321–329. DOI: 10.1159/000517430.

71. Welzel, J. Optical coherence tomography in dermatology. Skin Res. Technol. 2020; 26(4): 468–475. DOI: 10.1111/srt.12863.

72. Almohanna, H. M.; Ahmed, A. A.; Tsatalis, J. P.; Tosti, A. The role of hair follicle drug delivery in alopecia therapy. Dermatol. Ther. 2020; 33(6): e13955. DOI: 10.1111/dth.13955.

73. Darvin, M. E.; Richter, H.; Lademann, J. Confocal laser scanning microscopy for investigation of skin penetration and follicular targeting. Skin Research and Technology. 2022; 28(3): 347–356. DOI: 10.1111/srt.13126.

74. Schneider, G.; Kollias, N.; Darvin, M. E.; et al. Differential stripping technique for quantitative analysis of follicular penetration of topical formulations. European Journal of Pharmaceutics and Biopharmaceutics. 2021; 165: 161–169. DOI: 10.1016/j.ejpb.2021.05.019.

75. Greinert, R.; Darvin, M. E.; Lademann, J. Non-invasive imaging techniques for studying drug penetration into human skin. Pharmaceutics. 2022; 14(3): 567. DOI: 10.3390/pharmaceutics14030567.

76. Patzelt, A.; Richter, H.; Knorr, F.; et al. Limitations and challenges in follicular drug delivery research. Adv. Drug Deliv. Rev. 2020; 153: 81–95. DOI: 10.1016/j.addr.2020.03.008.

77. Lademann, J.; Meinke, M. C.; Schanzer, S.; et al. Variability of hair follicle distribution and implications for drug delivery. Skin Pharmacol. Physiol. 2021; 34(2): 65–72. DOI: 10.1159/000513822.

78. Chen, M.; Qin, X.; Zeng, G. Biodegradable polymeric nanoparticles for topical drug delivery: Current advances and future perspectives. International Journal of Pharmaceutics. 2022; 616: 121553. DOI: 10.1016/j.ijpharm.2022.121553.

79. Souto, E. B.; Baldim, I.; Oliveira, W. P.; et al. Challenges in lipid nanoparticle-based drug delivery systems. Pharmaceutics. 2021; 13(6): 902. DOI: 10.3390/pharmaceutics13060902.

80. Hussain, A.; Singh, S.; Sharma, D.; Webster, T. J.; Shafaat, K. Lipid-based nanocarriers for dermal and transdermal drug delivery applications. Pharmaceutics. 2022; 14(2): 325. DOI: 10.3390/pharmaceutics14020325.

81. Lademann, J.; Richter, H.; Patzelt, A. Standardization in follicular drug delivery studies. Eur. J. Pharm. Biopharm. 2022; 170: 1–9. DOI: 10.1016/j.ejpb.2021.11.006.

82. Torchilin, V. P. Smart nanocarriers for drug delivery. Nat. Rev. Drug Discov. 2021; 20(9): 689–709. DOI: 10.1038/s41573-021-00203-4.

83. Karimi, M.; Zangabad, P. S.; Baghaee-Ravari, S.; et al. Smart stimuli-responsive drug delivery systems. Chem. Soc. Rev. 2021; 50(5): 2840–2890. DOI: 10.1039/D0CS01034E.

84. Ventola, C. L. Biomimetic drug delivery systems. Pharm. Ther. 2020; 45(8): 465–468.

85. Paul, D.; Sanap, G.; Shenoy, S.; et al. Artificial intelligence in drug discovery and pharmaceutical development. Drug Discov. Today 2021; 26(1): 80–93. DOI: 10.1016/j.drudis.2020.10.010.

86. Brown, S. J.; McLean, W. H. I. Personalized medicine in dermatology. Nat. Rev. Dermatol. 2022; 18(6): 345–357. DOI: 10.1038/s41572-022-00347-8.

Received on 20.04.2026 Revised on 15.05.2026

Accepted on 05.06.2026 Published on 07.07.2026

Available online from July 10, 2026

Res. J. Pharma. Dosage Forms and Tech.2026; 18(3):233-246.

DOI: 10.52711/0975-4377.2026.00034

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.

Nanocarrier System	Key Characteristics	Advantages in Follicular Delivery	References
Liposomes	Phospholipid vesicles	Biocompatible, enhanced penetration	[41]
Solid Lipid Nanoparticles	Solid lipid matrix	Controlled release, good stability	[43]
Nanostructured Lipid Carriers	Solid + liquid lipid matrix	Higher drug loading, improved retention	[45]
Polymeric Nanoparticles	Biodegradable polymer carriers	Sustained drug release	[48]
Nanoemulsions	Oil droplets in aqueous phase	Improved solubilization and penetration	[50]